![Wei Lin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wei Lin
Technik-/Wissenschafts-/F&E-Leiter bei
REVOLUTION MEDICINES, INC.
Vermögen: 17 Mio $ am 30.06.2026
Profil
Wei Lin is currently an Independent Director at TCGX Acquisition Corp.
since 2026 and Chief Medical Officer at Revolution Medicines, Inc. since 2023.
Former positions include Independent Director at 2seventy Bio, Inc. from 2023 to 2025, Chief Medical Officer at Erasca, Inc. from 2021 to 2023, Senior Vice President-Clinical Development at Nektar Therapeutics from 2018 to 2021, Site Head-Oncology Product Development at Roche (China) Investment Co., Ltd. from 2006 to 2009, Head-Neck Cancers at Genentech, Inc., and Member-Head & Neck Medical Oncology Department at The University of Texas M.D.
Anderson Cancer Center.
Education includes undergraduate studies at Haverford College and a doctorate from Harvard Medical School conferred in 2004.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.09.2025 | 88’339 ( 0.04% ) | 17 Mio $ | 31.07.2026 | |
1.39% | 05.08.2026 | 30’000 ( 1.39% ) | 0 $ | 30.06.2026 |
Aktive Positionen von Wei Lin
| Unternehmen | Position | Beginn |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2023 |
Ehemalige bekannte Positionen von Wei Lin
| Unternehmen | Position | Ende |
|---|---|---|
| 2SEVENTY BIO, INC. | Direktor/Vorstandsmitglied | 13.05.2025 |
| ERASCA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.04.2023 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 05.01.2021 |
Roche (China) Co. Ltd.
 Roche (China) Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in pharmaceutical research and development | Corporate Officer/Principal | 01.01.2009 |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | - |
Ausbildung von Wei Lin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Haverford College
 Haverford College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche (China) Co. Ltd.
Roche (China) Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in pharmaceutical research and development | Commercial Services |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
2seventy Bio, Inc.
 2seventy Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for the treatment of cancer and genetic diseases | Health Technology |
